ARRY is more than 33% premarket on news, good on them. I hold shares at low $4s. Surprisingly, the stock has been down so i was concerned the NEMO (melanoma) trial was a failure. This is great news. Now they have 2 studies for 2 indications and presumably positive too
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.